Recurrent Glioblastoma Market to Grow Positively at a Paltry CAGR | Major players: Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine, expected to boost the market

DelveInsight's "Recurrent Glioblastoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Recurrent Glioblastoma market share of the individual therapies, current and forecasted Recurrent Glioblastoma market size from 2019 to 2032 segmented by seven major markets. The report also offers current Recurrent Glioblastoma therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Recurrent Glioblastoma market.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent Developments in the Recurrent Glioblastoma Treatment Landscape
In May 2023, Biodexa Pharmaceuticals announced the initiation of a Phase 1 clinical trial for Lomustine and MTX110. This study aims to evaluate the safety of MTX110 both as a standalone treatment and in combination with Lomustine for patients with recurrent glioblastoma. MTX110 will be delivered directly to the tumor site via a catheter, which will be inserted during an initial surgical procedure.

In June 2023, Genexine Inc. launched a Phase 2 clinical trial to investigate the effectiveness and safety of the combination of GX-17 and Bevacizumab in individuals with recurrent glioblastoma.

Key highlights from the recurrent glioblastoma market report:
The Recurrent Glioblastoma market is anticipated to grow as awareness of the condition rises and more effective treatments are developed.
Key players in the Recurrent Glioblastoma space include Accendatech USA Inc., Avance Clinical Pty Ltd, Genexine Inc., Biodexa Pharmaceuticals, PharmAbcine, Cordgenics LLC, Shanghai Simnova Biotechnology Co. Ltd, Novartis Pharmaceuticals, Cantex Pharmaceuticals, WPD Pharmaceuticals, AstraZeneca, Peregrine Pharmaceuticals, and others.
Recurrent Glioblastoma Overview
Recurrent Glioblastoma refers to the return of glioblastoma multiforme (GBM), an aggressive type of brain tumor, after initial treatment. It is characterized by rapid growth and a poor prognosis.

Causes
The exact causes of glioblastoma are not fully understood, but several factors may contribute to its development and recurrence, including:

Genetic Mutations: Changes in specific genes (like TP53, PTEN, and EGFR) can play a role.
Environmental Factors: Exposure to ionizing radiation and certain chemicals may increase risk.
Age: GBM is more common in older adults.
Gender: Men are more frequently diagnosed than women.
Signs and Symptoms
Symptoms of recurrent glioblastoma can vary but may include:

Headaches: Often severe and worsening.
Nausea and Vomiting: Due to increased intracranial pressure.
Neurological Deficits: Such as weakness, numbness, or coordination issues.
Cognitive Changes: Memory problems, confusion, or changes in behavior.
Seizures: New or worsening seizures are common.
Diagnosis
Diagnosis of recurrent glioblastoma typically involves:

Imaging Studies: MRI scans are the standard method to visualize brain tumors and assess recurrence.
Neurological Exam: A thorough examination to evaluate symptoms and brain function.
Biopsy: If needed, a tissue sample may be obtained to confirm the diagnosis and analyze the tumor's genetic makeup.
Treatment Options
Treatment for recurrent glioblastoma can be challenging and may include:

Surgery: If the tumor is accessible, resection can help alleviate symptoms and may extend survival.

Radiation Therapy: This may be used again if the tumor recurs in a different area or if it can help reduce the size of the tumor.

Chemotherapy: Options include:

Temozolomide: Often used in combination with other therapies.
Bevacizumab: An anti-angiogenic drug that may reduce swelling and help with symptoms.
Targeted Therapies: Investigational drugs targeting specific genetic mutations associated with GBM are being studied.

Clinical Trials: Patients may be eligible for new therapies, including immunotherapy, novel agents, or other investigational approaches.

Supportive Care: Palliative care is essential to manage symptoms and maintain quality of life.

Recurrent glioblastoma poses significant challenges for treatment and management. Early detection and a multidisciplinary approach are crucial for optimizing care and improving outcomes for patients facing this aggressive cancer.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recurrent Glioblastoma Treatment Market

The Recurrent Glioblastoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Recurrent Glioblastoma market trends by analyzing the impact of current Recurrent Glioblastoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Recurrent Glioblastoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Recurrent Glioblastoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Recurrent Glioblastoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Request for a Free Recurrent Glioblastoma Market Sample Report @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Promising Therapies in the Recurrent Glioblastoma Pipeline
ASC40 : Ascletis Pharmaceuticals
VXM01: VAXIMM AG
VB-111: VBL Therapeutics
hp1a8: OX2 Therapeutics
ERAS-801: Erasca
GX-I7: Genexine

Recurrent Glioblastoma Emerging Therapy Assessment
ASC40 : Ascletis Pharmaceuticals
ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novolipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumorcells by blocking de novo lipogenesis. Approximately 80% of 180 patients with recurrent Glioblastoma (rGBM)in the Phase III clinical trial are expected to be randomized and enrolled by the end of December 2022.Currently the product is in Phase III stage of development for the treatment of recurrent Glioblastoma.


Discover more about Recurrent Glioblastoma therapies in the pipeline, visit Recurrent Glioblastoma Drugs @ https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Recurrent Glioblastoma Market
Ascletis Pharmaceuticals
VAXIMM AG
VBL Therapeutics
OX2 Therapeutics
Erasca
Genexine

To understand key companies related to the Recurrent Glioblastoma Market, get a snapshot of the Recurrent Glioblastoma Regulatory and Patent Analysis @ https://www.delveinsight.com/report-store/recurrent-glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Recurrent Glioblastoma Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Recurrent Glioblastoma Companies: Ascletis Pharmaceuticals, VAXIMM AG, VBL Therapeutics, OX2 Therapeutics, Erasca, Genexine, and others
Key Recurrent Glioblastoma Pipeline Therapies: ASC40, VXM01, VB-111, hp1a8, ERAS-801, GX-I7, and others
Therapeutic Assessment: Recurrent Glioblastoma current marketed and emerging therapies
Recurrent Glioblastoma Market Dynamics: Recurrent Glioblastoma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Recurrent Glioblastoma Market Access and Reimbursement

Table of Contents
1. Recurrent Glioblastoma Market Key Insights
2. Recurrent Glioblastoma Market Report Introduction
3. Recurrent Glioblastoma Market Overview at a Glance
4. Recurrent Glioblastoma Market Executive Summary
5. Disease Background and Overview
6. Recurrent Glioblastoma Treatment and Management
7. Recurrent Glioblastoma Epidemiology and Patient Population
8. Patient Journey
9. Recurrent Glioblastoma Emerging Drugs
10. 7MM Recurrent Glioblastoma Market Analysis
11. Recurrent Glioblastoma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Recurrent Glioblastoma Market Drivers
15. Recurrent Glioblastoma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us
Name: Kritika Rehani
E-mail: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.